Sarcoma News

Two-Drug Combination Effective Against Ewing Sarcoma - Specialty Pharmacy Times (blog)



Two-Drug Combination Effective Against Ewing Sarcoma 
Specialty Pharmacy Times (blog)
An investigational drug plus an FDA-approved chemotherapy were observed to stop the growth of Ewing sarcoma in both cell lines and animal models, according to a study published by Science Signaling. The authors report that this finding should pave the ...

 


Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter? - Journal of Minimally Invasive Gynecology



Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter? 
Journal of Minimally Invasive Gynecology
A total of 1,959 myomectomies and hysterectomies were performed; four unsuspected uterine sarcomas were identified for an incidence of 2.0 per 1000 cases. The sarcoma incidence during open abdominal surgery (3 in 743 cases, or .40%) was similar to the ...

 


Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma ... - GlobeNewswire (press release)



Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma ... 
GlobeNewswire (press release)
The randomized Phase 3 trial will evaluate CMB305 monotherapy vs. placebo in patients with NY-ESO-1+ locally advanced unresectable or metastatic synovial sarcoma, a sub type of soft tissue sarcoma, who have no evidence of progression after first-line ...

and more » 


First-line Doxorubicin for Advanced Sarcoma, Not Combo? - Medscape



Medscape
 
First-line Doxorubicin for Advanced Sarcoma, Not Combo? 
Medscape
Doxorubicin should remain first-line therapy for patients with soft-tissue sarcoma, conclude trialists who compared it with the combination of gemcitabine and docetaxel. They make this statement despite the fact that the trial, known as GeDDis, found ...

 


Immune Design's Sarcoma Candidate to Enter Phase III in 2018 - Nasdaq



Immune Design's Sarcoma Candidate to Enter Phase III in 2018 
Nasdaq
Immune DesignIMDZ announced that it plans to initiate a pivotal phase III study to support a regulatory application for CMB305, in patients with synovial sarcoma. The company plans to start the study in mid-2018 and enroll 248 patients aged 12 years ...

and more » 


Two agents deliver knockout punches to Ewing sarcoma - Science Daily



Two agents deliver knockout punches to Ewing sarcoma 
Science Daily
In the United States, about 500 children and young adults are diagnosed with Ewing sarcoma annually. Between 60 to 70 percent of patients survive more than five years, but with many late effects from treatment. Patients with Ewing sarcoma are currently ...

and more » 


Male hormones may promote infection by virus that causes Kaposi's sarcoma - Science Daily



ummid.com
 
Male hormones may promote infection by virus that causes Kaposi's sarcoma 
Science Daily
Earlier studies have suggested that men are more vulnerable to infection with Kaposi's sarcoma-associated herpesvirus (KSHV), and more DNA from this virus is detected in infected men than in infected women. This suggests that male hormones may ...
Here's why men are at increased risk of developing cancer Deccan Chronicle
Research Roundup: Geckos using narrow tree perches have longer limbs than expected; Male hormones may promote ... PLOS Research News

all 6 news articles » 


Sarcoma Advisor - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Sarcoma Advisor 
Cancer Therapy Advisor
For the single-arm, phase 2 SARC028 study (ClinicalTrials.gov Identifier: NCT02301039), investigators assessed the response of 80 evaluable patients with soft tissue sarcoma or bone sarcoma treated with intravenous pembrolizumab 200 mg every 3 weeks.

 


Loved ones affected by cancer spur women to start first Nashville-area Race to Cure Sarcoma - Spring Hill Home Page



Spring Hill Home Page
 
Loved ones affected by cancer spur women to start first Nashville-area Race to Cure Sarcoma 
Spring Hill Home Page
A month after graduating from Fred J. Page High School in 2015, 18-year-old Matt Fornero was diagnosed with rhabdomyosarcoma, a type of cancer usually diagnosed in children that affects the muscles. His mother, Jayme Fornero, said doctors discovered a ...

and more » 


Boosting sarcoma cell death - Medical Xpress



Boosting sarcoma cell death 
Medical Xpress
In a search for new therapeutic options for Ewing sarcoma, Dai Chung, M.D., and colleagues tested a compound previously identified at Vanderbilt, ML327, that induces the expression of the cell adhesion protein E-cadherin. E-cadherin, a hallmark of ...